Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

MorphoSys AG : to Present at Three Investor Conferences in November

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/14/2011 | 03:05pm CET

MorphoSys AG / MorphoSys to Present at Three Investor Conferences in November . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that management will present at three international investor conferences in November.

9th WestLB Deutschland Conference
Date:                          November 16, 2011 at 10:15am CET (09:15am GMT; 
                                  04:15am EST)
Venue:                        Frankfurt, Germany
Participants:                Jens Holstein, CFO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate
                                  Communications & IR

Deutsches Eigenkapitalforum
Date:                          November 22, 2011 at 09:45am CET (08:45am GMT;
                                  03:45am EST)
Venue:                        Frankfurt, Germany
Participants:                Dr. Simon Moroney, CEO of MorphoSys AG
                                  Jens Holstein, CFO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate
                                  Communications & IR

23rd Annual Piper Jaffray Healthcare Conference
Date:                          November 30, 2011 at 01:30pm EST (06:30pm GMT;
                                  07:30pm CET)
Venue:                        New York, USA
Participants:                Dr. Simon Moroney, CEO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate 
                                  Communications & IR

A PDF version of the Company presentation will be provided at www.morphosys.com/presentations:
http://www.morphosys.com/presentations. Links to the webcast, if available, are filed under www.morphosys.com/conference-calls:
http://www.morphosys.com/conference-calls.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The Company's AbD Serotec unit uses HuCAL and other technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Through its own development efforts and successful partnerships in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline:
http://www.morphosys.com/pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com:
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, arYla®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com:
mailto:investors@morphosys.com

Conference Announcement November:
http://hugin.info/130295/R/1563518/484733.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

HUG#1563518

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
11/29 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/28 MORPHOSYS : Announces That Its Licensee Janssen Has Submitted a Marketing Author..
11/25 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/22 CORRECTION OF A RELEASE FROM 21.11.2 : 05 CET - MorphoSys AG: Publication pursua..
11/21 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/21 MORPHOSYS AG : Notification of managers`transactions according to article 19 MAR
11/21 MORPHOSYS AG : Notification of managers`transactions according to article 19 MAR
11/17 MORPHOSYS : Announces That Its Licensee Janssen Has Submitted Biologics License ..
11/17 MORPHOSYS AG : Publication pursuant to §26a WpHG (the German Securities Trading ..
11/16 DEUTSCHE BANK : MorphoSys Raises EUR 115 million in Private Placement
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/22 Morphosys Ag (MPSYY) Investor Presentation - Slideshow
11/08 MorphoSys' (MPSYF) CEO Simon Moroney on Q3 2016 Results - Earnings Call Trans..
11/07 MorphoSys AG reports 9M results
10/04 Allergan Shows It Has Stomach For More GI Dealmaking
09/21 MorphoSys (MPSYY) Presents at Bank of America Merrill Lynch 2016 Global Healt..
Advertisement
Financials (€)
Sales 2016 49,9 M
EBIT 2016 -64,5 M
Net income 2016 -52,9 M
Finance 2016 238 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 19,3x
EV / Sales 2017 19,2x
Capitalization 1 200 M
More Financials
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 62,9 €
Spread / Average Target 53%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-28.83%1 280
INCYTE CORPORATION-5.68%19 219
QUINTILES IMS HOLDINGS..11.90%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.44.41%9 442
LONZA GROUP AG11.34%9 247
More Results